| Phase 12 trials |
|
Phase 1
|
NCT01675765 |
Sep 2014 → Sep 2018 |
malignant pleural mesothelioma |
Aduro Biotech, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00585845 |
Dec 2007 → Feb 2009 |
malignant epithelioid mesothelioma, non-small cell lung carcinoma, ovarian adenocarcinoma, pancreatic adenocarcinoma |
Anza Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT02575807 |
Mar 2016 → Apr 2018 |
fallopian tube cancer, peritoneum cancer |
Aduro Biotech, Inc. |
Terminated
|
No outcome recorded
Stop: Enrollment |
| Phase 27 trials · 1 missed |
|
Phase 2
|
NCT05014776 |
Aug 2022 → Apr 2024 |
malignant pancreatic neoplasm |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03190265 |
Dec 2017 → Aug 2022 |
malignant pancreatic neoplasm |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03122548 |
Aug → Dec 2017 |
esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma |
Aduro Biotech, Inc. |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 2
|
NCT03175172 |
May 2017 → Jan 2018 |
malignant pleural mesothelioma |
Aduro Biotech, Inc. |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 2
|
NCT02243371 |
Jan 2015 → Jul 2017 |
pancreatic adenocarcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02004262 |
Feb 2014 → Jan 2016 |
— |
Aduro Biotech, Inc. |
Completed
|
Missed primary
|
|
Phase 2
|
NCT01417000 |
Sep 2011 → Oct 2016 |
malignant pancreatic neoplasm |
Aduro Biotech, Inc. |
Completed
|
No outcome recorded
|
| Comparator or background therapy1 trial |
|
Phase 2
|
NCT03006302 Background |
Jan 2018 → Aug 2023 |
pancreatic adenocarcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|